{"pmid":32417222,"title":"Implementation of an Emergency Use Authorization Test During an Impending National Crisis.","text":["Implementation of an Emergency Use Authorization Test During an Impending National Crisis.","The laboratory response to the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic may be termed heroic. From the identification of the novel coronavirus to implementation of routine laboratory testing around the world to the development of potential vaccines, laboratories have played a critical role in the efforts to curtail this pandemic. In this brief report, we review our own effort at a mid-sized, rural, academic medical center to implement a molecular test for the virus; and, we share insights and lessons learned from that process which might be helpful in similar situations in the future.","J Mol Diagn","Lefferts, Joel A","Gutmann, Edward J","Martin, Isabella W","Wells, Wendy A","Tsongalis, Gregory J","32417222"],"abstract":["The laboratory response to the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic may be termed heroic. From the identification of the novel coronavirus to implementation of routine laboratory testing around the world to the development of potential vaccines, laboratories have played a critical role in the efforts to curtail this pandemic. In this brief report, we review our own effort at a mid-sized, rural, academic medical center to implement a molecular test for the virus; and, we share insights and lessons learned from that process which might be helpful in similar situations in the future."],"journal":"J Mol Diagn","authors":["Lefferts, Joel A","Gutmann, Edward J","Martin, Isabella W","Wells, Wendy A","Tsongalis, Gregory J"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417222","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jmoldx.2020.05.001","topics":["Prevention"],"weight":1,"_version_":1667058206831017984,"score":9.490897,"similar":[{"pmid":32381642,"title":"Understanding, verifying and implementing Emergency Use Authorization molecular diagnostics for the detection of SARS-CoV-2 RNA.","text":["Understanding, verifying and implementing Emergency Use Authorization molecular diagnostics for the detection of SARS-CoV-2 RNA.","The SARS-CoV-2 pandemic has brought a new wave of challenges to health care, particularly in the area of rapid diagnostic test development and implementation. Acute diagnosis of COVID-19 infection is critically dependent on detection of SARS-CoV-2 RNA from clinical specimens (e.g. nasopharyngeal swabs). While laboratory-developed testing for SARS-CoV-2 is an essential component of diagnostic testing for this virus, the majority of clinical microbiology laboratories are dependent on commercially available SARS-CoV-2 molecular assays. In contrast to assays approved or cleared by the Food and Drug Administration for in vitro diagnostic use, assays for the detection of SARS-CoV-2 nucleic acids have Emergency Use Authorization (EUA) from the FDA. Outside of highly specialized academic and commercial laboratory settings, clinical microbiology laboratories are likely unfamiliar with EUA classification and thus assay verification can be daunting. Further compounding anxiety for laboratories are major issues with supply chain that are dramatically affecting the availability of test reagents and requiring laboratories to implement multiple commercial EUA tests. Here, we describe guidance for the verification of assays with EUA for the detection of SARS-CoV-2 nucleic acid from clinical specimens.","J Clin Microbiol","Mitchell, Stephanie L","St George, Kirsten","Rhoads, Daniel D","Butler-Wu, Susan M","Dharmarha, Vaishali","McNult, Peggy","Miller, Melissa B","32381642"],"abstract":["The SARS-CoV-2 pandemic has brought a new wave of challenges to health care, particularly in the area of rapid diagnostic test development and implementation. Acute diagnosis of COVID-19 infection is critically dependent on detection of SARS-CoV-2 RNA from clinical specimens (e.g. nasopharyngeal swabs). While laboratory-developed testing for SARS-CoV-2 is an essential component of diagnostic testing for this virus, the majority of clinical microbiology laboratories are dependent on commercially available SARS-CoV-2 molecular assays. In contrast to assays approved or cleared by the Food and Drug Administration for in vitro diagnostic use, assays for the detection of SARS-CoV-2 nucleic acids have Emergency Use Authorization (EUA) from the FDA. Outside of highly specialized academic and commercial laboratory settings, clinical microbiology laboratories are likely unfamiliar with EUA classification and thus assay verification can be daunting. Further compounding anxiety for laboratories are major issues with supply chain that are dramatically affecting the availability of test reagents and requiring laboratories to implement multiple commercial EUA tests. Here, we describe guidance for the verification of assays with EUA for the detection of SARS-CoV-2 nucleic acid from clinical specimens."],"journal":"J Clin Microbiol","authors":["Mitchell, Stephanie L","St George, Kirsten","Rhoads, Daniel D","Butler-Wu, Susan M","Dharmarha, Vaishali","McNult, Peggy","Miller, Melissa B"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381642","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1128/JCM.00796-20","topics":["Diagnosis"],"weight":1,"_version_":1666419683233890305,"score":144.64326},{"pmid":32348469,"pmcid":"PMC7197526","title":"Laboratory information system requirements to manage the COVID-19 pandemic: a report from the Belgian national reference testing center.","text":["Laboratory information system requirements to manage the COVID-19 pandemic: a report from the Belgian national reference testing center.","OBJECTIVE: To describe the development, implementation and requirements of laboratory information system (LIS) functionality to manage test ordering, registration, sample flow, and result reporting during the COVID-19 pandemic. CONTEXT AND SETTING: Our large (>12,000,000 tests/year) academic hospital laboratory is the Belgian National Reference Center (NRC) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We performed a moving total of > 25,000 SARS-CoV-2 PCR tests in parallel to standard routine testing since the start of the outbreak. A LIS implementation team dedicated to develop tools to remove the bottlenecks, primarily situated in the pre- and post-analytical phase, was established early in the crisis. RESULTS: We outline the design, implementation and requirements of LIS functionality related to managing increased test demand during the COVID-19 crisis, including tools for test ordering, standardized order sets integrated into a computerized provider order entry module, notifications on shipping requirements, automated triaging based on digital metadata forms, and the establishment of databases with contact details of other laboratories and primary care physicians to enable automated reporting. We also describe our approach to data mining and reporting of actionable daily summary statistics to governing bodies and other policymakers. DISCUSSION: Rapidly developed, agile extendable LIS functionality and its meaningful use alleviates the administrative burden on laboratory personnel and improves turn-around-time of SARS-CoV-2 testing. It will be important to maintain an environment that is conducive for the rapid adoption of meaningful LIS tools post-COVID crisis.","J Am Med Inform Assoc","Weemaes, Matthias","Martens, Steven","Cuypers, Lize","Van Elslande, Jan","Hoet, Katrien","Welkenhuysen, Joris","Goossens, Ria","Wouters, Stijn","Houben, Els","Jeuris, Kirsten","Laenen, Lies","Bruyninckx, Katrien","Beuselinck, Kurt","Andre, Emmanuel","Depypere, Melissa","Desmet, Stefanie","Lagrou, Katrien","Van Ranst, Marc","Verdonck, Ann K L C","Goveia, Jermaine","32348469"],"abstract":["OBJECTIVE: To describe the development, implementation and requirements of laboratory information system (LIS) functionality to manage test ordering, registration, sample flow, and result reporting during the COVID-19 pandemic. CONTEXT AND SETTING: Our large (>12,000,000 tests/year) academic hospital laboratory is the Belgian National Reference Center (NRC) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We performed a moving total of > 25,000 SARS-CoV-2 PCR tests in parallel to standard routine testing since the start of the outbreak. A LIS implementation team dedicated to develop tools to remove the bottlenecks, primarily situated in the pre- and post-analytical phase, was established early in the crisis. RESULTS: We outline the design, implementation and requirements of LIS functionality related to managing increased test demand during the COVID-19 crisis, including tools for test ordering, standardized order sets integrated into a computerized provider order entry module, notifications on shipping requirements, automated triaging based on digital metadata forms, and the establishment of databases with contact details of other laboratories and primary care physicians to enable automated reporting. We also describe our approach to data mining and reporting of actionable daily summary statistics to governing bodies and other policymakers. DISCUSSION: Rapidly developed, agile extendable LIS functionality and its meaningful use alleviates the administrative burden on laboratory personnel and improves turn-around-time of SARS-CoV-2 testing. It will be important to maintain an environment that is conducive for the rapid adoption of meaningful LIS tools post-COVID crisis."],"journal":"J Am Med Inform Assoc","authors":["Weemaes, Matthias","Martens, Steven","Cuypers, Lize","Van Elslande, Jan","Hoet, Katrien","Welkenhuysen, Joris","Goossens, Ria","Wouters, Stijn","Houben, Els","Jeuris, Kirsten","Laenen, Lies","Bruyninckx, Katrien","Beuselinck, Kurt","Andre, Emmanuel","Depypere, Melissa","Desmet, Stefanie","Lagrou, Katrien","Van Ranst, Marc","Verdonck, Ann K L C","Goveia, Jermaine"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348469","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/jamia/ocaa081","keywords":["covid-19","change management","computerized provider order entry","health information technology implementation","laboratory information system"],"locations":["Belgian"],"countries":["Belgium"],"countries_codes":["BEL|Belgium"],"topics":["Prevention"],"weight":1,"_version_":1666138495013355521,"score":128.89249},{"pmid":32372664,"title":"Mexico: Lessons learned from the 2009 pandemic that help us fight COVID-19.","text":["Mexico: Lessons learned from the 2009 pandemic that help us fight COVID-19.","In April 2009, Mexican, American, and Canadian authorities announced a novel influenza that became the first pandemic of the century. We report on lessons learned in Mexico. The Mexican Pandemic Influenza Preparedness and Response Plan, developed and implemented since 2005, was a decisive element for the early response. Major lessons-learned were the need for flexible plans that consider different scenarios; the need to continuously strengthen routine surveillance programs and laboratory capacity and strengthen coordination between epidemiological departments, clinicians, and laboratories; maintain strategic stockpiles; establish a fund for public health emergencies; and collaboration among neighboring countries. Mexico responded with immediate reporting and transparency, implemented aggressive control measures and generous sharing of data and samples. Lessons learned induced changes leading to a better response to public health critical events.","Healthc Manage Forum","Hernandez-Avila, Mauricio","Alpuche-Aranda, Celia M","32372664"],"abstract":["In April 2009, Mexican, American, and Canadian authorities announced a novel influenza that became the first pandemic of the century. We report on lessons learned in Mexico. The Mexican Pandemic Influenza Preparedness and Response Plan, developed and implemented since 2005, was a decisive element for the early response. Major lessons-learned were the need for flexible plans that consider different scenarios; the need to continuously strengthen routine surveillance programs and laboratory capacity and strengthen coordination between epidemiological departments, clinicians, and laboratories; maintain strategic stockpiles; establish a fund for public health emergencies; and collaboration among neighboring countries. Mexico responded with immediate reporting and transparency, implemented aggressive control measures and generous sharing of data and samples. Lessons learned induced changes leading to a better response to public health critical events."],"journal":"Healthc Manage Forum","authors":["Hernandez-Avila, Mauricio","Alpuche-Aranda, Celia M"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32372664","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1177/0840470420921542","locations":["Mexican","American","Canadian","Mexico","Mexico","Mexico"],"countries":["United States","Canada","Mexico"],"countries_codes":["USA|United States","CAN|Canada","MEX|Mexico"],"topics":["Prevention"],"weight":1,"_version_":1666138496486604800,"score":119.57786},{"pmid":32431260,"title":"The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Outbreak at King Abdul-Aziz Medical City-Riyadh from Emergency Medical Services Perspective.","text":["The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Outbreak at King Abdul-Aziz Medical City-Riyadh from Emergency Medical Services Perspective.","Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a form of an infectious respiratory disease, discovered in November 2012 in Saudi Arabia. According to the World Health Organization (WHO; Geneva, Switzerland) reports, a total of 2,519 laboratory-confirmed cases and 866 MERS-CoV-related deaths were recorded as of March 5, 2016.1 The majority of reported cases originated from Saudi Arabia (2,121 cases). Also, MERS-CoV is believed to be of zoonotic origin and has been linked to camels in the Arabian area.1,2 In this report, the authors discuss the lessons learned from the MERS-CoV outbreak at King Abdul-Aziz Medical City-Riyadh (KAMC-R) from August through September 2015 from the Emergency Medical Services (EMS) perspective. The discussion includes the changes in policies and paramedic's practice, the training and education in infection control procedures, and the process of transportation of these cases. The authors hope to share their experience in this unique situation and highlight the preparedness and response efforts that took place by the division of EMS during the outbreak.","Prehosp Disaster Med","Alabdali, Abdullah","Almakhalas, Kharsan","Alhusain, Faisal","Albaiz, Saad","Almutairi, Khalid","Aljerian, Nawfal","32431260"],"abstract":["Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a form of an infectious respiratory disease, discovered in November 2012 in Saudi Arabia. According to the World Health Organization (WHO; Geneva, Switzerland) reports, a total of 2,519 laboratory-confirmed cases and 866 MERS-CoV-related deaths were recorded as of March 5, 2016.1 The majority of reported cases originated from Saudi Arabia (2,121 cases). Also, MERS-CoV is believed to be of zoonotic origin and has been linked to camels in the Arabian area.1,2 In this report, the authors discuss the lessons learned from the MERS-CoV outbreak at King Abdul-Aziz Medical City-Riyadh (KAMC-R) from August through September 2015 from the Emergency Medical Services (EMS) perspective. The discussion includes the changes in policies and paramedic's practice, the training and education in infection control procedures, and the process of transportation of these cases. The authors hope to share their experience in this unique situation and highlight the preparedness and response efforts that took place by the division of EMS during the outbreak."],"journal":"Prehosp Disaster Med","authors":["Alabdali, Abdullah","Almakhalas, Kharsan","Alhusain, Faisal","Albaiz, Saad","Almutairi, Khalid","Aljerian, Nawfal"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431260","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1017/S1049023X20000709","keywords":["emergency medical services","middle east respiratory syndrome coronavirus","disaster","paramedics","personal protective equipment"],"locations":["Saudi Arabia","Geneva","Switzerland","Saudi Arabia","Arabian"],"countries":["Switzerland","Saudi Arabia"],"countries_codes":["CHE|Switzerland","SAU|Saudi Arabia"],"topics":["Prevention"],"weight":1,"_version_":1667342288414572544,"score":103.92042},{"pmid":32356761,"title":"Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management.","text":["Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future.","IEEE Rev Biomed Eng","Zhang, Jingwei","Gharizadeh, Baback","Lu, Daru","Yue, Junqiu","Yu, Mingxia","Liu, Yue","Zhou, Meiying","32356761"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To counter COVID-19 spreading, an infrastructure to provide rapid and thorough molecular diagnostics and serology testing is the cornerstone of outbreak and pandemic management. We hereby review the clinical insights with regard to using molecular tests and immunoassays in the context of COVID-19 management life cycle: the preventive phase, the preparedness phase, the response phase and the recovery phase. The spatial and temporal distribution of viral RNA, antigens and antibodies during human infection is summarized to provide a biological foundation for accurate detection of the disease. We shared the lessons learned and the obstacles encountered during real world high-volume screening programs. Clinical needs are discussed to identify existing technology gaps in these tests. Leverage technologies, such as engineered polymerases, isothermal amplification, and direct amplification from complex matrices may improve the productivity of current infrastructure, while emerging technologies like CRISPR diagnostics, visual end point detection, and PCR free methods for nucleic acid sensing may lead to at-home tests. The lessons learned, and innovations spurred from the COVID-19 pandemic could upgrade our global public health infrastructure to better combat potential outbreaks in the future."],"journal":"IEEE Rev Biomed Eng","authors":["Zhang, Jingwei","Gharizadeh, Baback","Lu, Daru","Yue, Junqiu","Yu, Mingxia","Liu, Yue","Zhou, Meiying"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356761","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1109/RBME.2020.2991444","topics":["Diagnosis"],"weight":1,"_version_":1666138495180079105,"score":102.493416}]}